Skip to main content

Table 2 Top five enriched canonical pathways in drug-treated cells compared with mock-treated cells

From: Novel prodrugs of decitabine with greater metabolic stability and less toxicity

Drug   Ingenuity canonical pathways P value Overlapping rate (%) (enriched gene no./total no.)
DAC 1 Interferon signaling 4.47E−07 38.2% (13/34)
  2 Hepatic fibrosis/hepatic stellate cell activation 2.68E−05 16.7% (30/180)
  3 TREM1 signaling 5.79E−04 20.0% (14/70)
  4 Activation of IRF by cytosolic pattern recognition receptors 1.02E−03 20.7% (12/58)
  5 Granulocyte adhesion and diapedesis 1.06E−03 14.7% (24/163)
OR-2003 1 Interferon signaling 3.72E−06 35.3% (12/34)
  2 Hepatic fibrosis/hepatic stellate cell activation 3.23E−05 16.7% (30/180)
  3 TREM1 signaling 6.39E−04 20.0% (14/70)
  4 Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis 1.02E−03 12.8% (38/298)
  5 Activation of IRF by cytosolic pattern recognition receptors 1.12E−03 20.7% (12/58)
OR-2100 1 Interferon signaling 4.40E−07 38.2% (13/34)
  2 Hepatic fibrosis/hepatic stellate cell activation 6.66E−05 16.1% (29/180)
  3 TREM1 signaling 5.70E−04 20.0% (14/70)
  4 Activation of IRF by cytosolic pattern recognition receptors 1.01E−03 20.7% (12/58)
  5 Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis 1.56E−03 12.4% (37/298)